Endless Challenges of Employees: Leni.. Participation in Arab Health 2024 Exh.. Inspections in Jecheon Production Sit.. GL Rapha in Kazakhstan on Biopharmace..

Overseas trading and marketing of pharmaceutical products, health supplements and medical devices

GL Rapha becomes the first international partner of RDIF to.. Hankook Korus Pharm, Quality Check of Sputnik Vaccine Valid.. GL Rapha, has Established a joint venture ‘YAS RAPHA’ in.. ‘BeautiO Revital Ampoule’, makes a foray into the Japane.. Hankook Korus Pharm BeutiO Cosmetics has been selected as B..

2023年3月15日 · GL Rapha is a company focused on biopharmaceutical manufacturing within the pharmaceutical industry. It offers services in the development and production of biopharmaceutical products, ensuring quality through rigorous production site inspections. The company engages in international projects to expand its biopharmaceutical reach.

2021年10月26日 · South Korean biotech firm GL Rapha has secured regulatory approval from Russia to produce and market the Sputnik family of coronavirus vaccines, the company and Russian sovereign fund RDIF said...

当地时间11月13日，俄罗斯主权财富基金（RDIF）称其已与韩国生物技术公司GL Rapha签署协议，每年在韩国生产1.5亿剂量的“卫星V”疫苗。

Korea supplier of Bio Similar, Cephalosporin Anti-Biotic, Anti-Cancer. GL Rapha, founded in 2001, is engaged in pharmaceutical industry And we are a representative of several pharmaceutical manufacturers specializing in the export of pharmaceutical products varying from raw materials, formulated bulk, to finished and ...

2020年11月13日，莫斯科 - 俄罗斯直接投资基金(RDIF，俄罗斯联邦的主权财富基金)和韩国领先的生物技术公司GL Rapha公司(包括Hankook Korus Pharm的子公司)宣布，他们已达成生产超过1.5亿剂世界上第一个已注册冠状病毒“Sputnik V”疫苗的协议。

2023年3月15日 · Hankook Korus Pharm, a Korean biopharma, said Wednesday its affiliate GL Rapha visited Saudi Arabia to discuss with the local government ministries and organizations about promoting a biopharmaceutical project in the country.

As part of the US$320 million (SAR 1.2 billion) agreement, GL Rapha, holding company of Hankook Korus Pharm, plans to establish a local facility to manufacture 30 biotechnology products in Saudi Arabia and launch five innovative products over the next five years.